Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026
Key Highlights
- ➤Baird Medical (BDMD) partnered with Alpmed to develop and commercialize IRE technology globally
- ➤Pakistan registered BD-GT microwave ablation system and T-1610 microwave ablation needle
- ➤First MWA procedures completed in Vietnam and Argentina during the third quarter
- ➤Baird Medical expanded physician training through programs in the U.S. and China
Expert Statements
Haimei Wu, Chairwoman and CEO of Baird Medical
“During the third quarter, we continued to execute on the priorities that we believe will drive Baird Medical’s long-term growth, including extension of our geographic reach, strengthening physician adoption and broadening our technology portfolio, while continuing to share our exciting story with the investment community”
Haimei Wu, Chairwoman and CEO of Baird Medical
“These milestones reflect the progress we are making to build a more diversified global business and create additional opportunities for growth.”
Mark Saxton, U.S. Chief Executive Officer of Baird Medical
“Our focus this quarter was on execution, including bringing our technology into new markets, working directly with physicians, and adding new capabilities to our portfolio”
Mark Saxton, U.S. Chief Executive Officer of Baird Medical
“At H.C. Wainwright, we had the opportunity to share that progress with investors and discuss where we see the business going from here. The work underway across our U.S. and international operations gives us a strong foundation as we head into the final months of the year.”
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (NASDAQ: BDMD), a medical device company focused on the development and commercialization of minimally invasive treatment technologies, today highlighted key business and operational developments from the third quarter of 2026, including expansion into new international markets, continued physician training initiatives and the addition of irreversible electroporation (IRE) technology to its broader technology portfolio through a strategic partnership.
“During the third quarter, we continued to execute on the priorities that we believe will drive Baird Medical’s long-term growth, including extension of our geographic reach, strengthening physician adoption and broadening our technology portfolio, while continuing to share our exciting story with the investment community,” said Haimei Wu, Chairwoman and CEO of Baird Medical. “These milestones reflect the progress we are making to build a more diversified global business and create additional opportunities for growth.”
Get started
Create a free account to read the full story.